Teijin (TSE:3401) Following Its Rally Is The Valuation Upside Still There

Teijin (TSE:3401) has attracted fresh attention after a recent share price move, with the stock last closing at ¥1,639.5. Investors are weighing this level against the company’s fundamentals and recent return profile.

See our latest analysis for Teijin.

Recent trading has built on Teijin’s positive year to date momentum, with a 1 day share price return of 0.52% and a 7 day share price return of 2.82%. This has contributed to a 22.21% year to date share price return and a 45.18% total shareholder return over the past year.

If Teijin’s move has you rethinking where the next opportunity could come from, this is a good moment to review 35 power grid technology and infrastructure stocks

Teijin’s recent share price gains and an intrinsic value estimate suggesting a 38.59% discount create a mixed picture, especially with analysts’ price targets sitting lower. Is the stock undervalued at this level, or is the market already pricing in future growth?

Most Popular Narrative: 13% Overvalued

Compared with Teijin’s last close at ¥1,639.5, the most followed narrative centers on a fair value of ¥1,454, which points to softer expectations than the market price implies.

In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 15.6x on those 2029 earnings, up from -3.6x today. This future PE is greater than the current PE for the JP Chemicals industry at 13.4x.

Read the complete narrative.

Want to see the full logic behind that valuation gap in Teijin? The core assumptions are in the earnings rebound, margin rebuild and the profit multiple the narrative is willing to pay.

Result: Fair Value of ¥1,454 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this narrative could be challenged if prolonged weakness in aramid and carbon fiber pricing, or sustained pressure on healthcare revenues, keeps Teijin’s margins under strain.

Find out about the key risks to this Teijin narrative.

Another View on Teijin’s Valuation

So far the focus has been on analyst fair value and price targets suggesting Teijin looks 13% overvalued at around ¥1,639.5 versus a fair value of ¥1,454. Our DCF model points in the opposite direction, with Teijin trading at a 38.6% discount to an estimate of future cash flow value of ¥2,669.9.

That split between the analyst target and the SWS DCF model puts you in the position of referee. Is the cash flow outlook too generous, or are the analyst assumptions too cautious for where Teijin is today? Which side of that gap do you rely on more in your own process?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

If this mixed sentiment on Teijin has you thinking twice, take a closer look at the full picture and decide quickly where you stand by weighing the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Teijin?

Teijin’s story is just one option, and if you stop here you could miss other opportunities that better fit your goals and risk preferences.

• Target growth potential early by reviewing carefully selected 1 elite penny stocks with strong financials that meet strict financial quality filters.
• Zero in on value opportunities with the 16 high quality undervalued stocks to see stocks combining quality fundamentals with prices below their estimated worth.
• Prioritise resilience by using the 48 resilient stocks with low risk scores focused on companies screened for stronger balance sheets and lower overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.